Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 11Active not recruiting 4Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Endocrine 2NET 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Lutetium × 1 year × Clear all
NCT06379217 2026-06-03

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Novartis

Phase 1 Active not recruiting
31 enrolled
EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT05849298 2026-05-27

PSMACare

Novartis

Phase 2 Active not recruiting
49 enrolled
Genitourinary

Prostatic Neoplasms

NCT06894511 2026-05-01

PSMAndARPI

Novartis

Phase 2 Active not recruiting
7 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡